GPR17 and demyelinating disease: In this respect, future studies will clarify if differences in GPR17 heterodimerization at different stages of demyelinating diseases could play a role in the “resistance” of GPR17 to physiological desensitization, which has been shown to lead to pathological receptor upregulation and the consequent blockade of oligodendrocyte differentiation to mature myelinating cells.